Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Tendera, M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Tendera, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2007. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Introduction

E-mail address: michal.tendera@gcm.pl

The first 10% of the full text of this article appears below.

Angiotensin-converting enzyme (ACE) inhibitors block the conversion of angiotensin-I to angiotensin-II, thus reducing the circulating and local levels of angiotensin-II. They can also inhibit kininase-II and increase bradykinin concentration. Their biological effects include a decrease in sympathetic activity and peripheral . . . [Full Text of this Article]

Michal Tendera

3rd Division of Cardiology
Medical University of Silesia
Ziolowa 47
40-635 Katowice
Poland


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?